Get the Stockscreener App
4.72
2.61%
0.12
After Hours:
4.70
-0.02
-0.42%
Precision Biosciences Inc stock is traded at $4.72, with a volume of 705.31K.
It is up +2.61% in the last 24 hours and down -34.26% over the past month.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
See More
Previous Close:
$4.60
Open:
$4.51
24h Volume:
705.31K
Relative Volume:
6.98
Market Cap:
$36.21M
Revenue:
$52.29M
Net Income/Loss:
$-73.52M
P/E Ratio:
-5.8272
EPS:
-0.81
Net Cash Flow:
$-100.45M
1W Performance:
-13.24%
1M Performance:
-34.26%
6M Performance:
-51.69%
1Y Performance:
-56.31%
1-Day Range:
$4.51
$5.0082
1-Week Range:
$4.13
$5.46
52-Week Range:
$4.13
$19.43
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
4.72 | 36.21M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-24 | Initiated | Guggenheim | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
Precision gains CTA approval in Hong Kong for chronic hepatitis B therapy trial - Yahoo Finance
Precision BioSciences gets nod for HBV trial in Hong Kong - Investing.com
Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B - Business Wire
Precision BioSciences stock hits 52-week low at $5.2 By Investing.com - Investing.com Nigeria
Precision BioSciences stock hits 52-week low at $5.2 - Investing.com India
(DTIL) Proactive Strategies - Stock Traders Daily
Precision BioSciences' SWOT analysis: gene editing firm's stock faces pivotal year - Investing.com UK
Precision BioSciences stock hits 52-week low at $6.4 By Investing.com - Investing.com South Africa
Precision BioSciences stock hits 52-week low at $6.4 - Investing.com
Precision BioSciences, Inc. (NASDAQ:DTIL) Short Interest Up 11.8% in November - MarketBeat
Gene Editing Market Forecast Report 2024, with Profiles of Merck, GenScript, Revvity, Lonza, Precision BioSciences, Cellectis, AMSBIO, Synthego, Takara Bio, Bio-Techne, Reprocell and More - Yahoo Finance
Precision BioSciences (NASDAQ:DTIL) Trading 3.6% HigherHere's What Happened - MarketBeat
Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains? - MSN
Insider Buying: John Kelly Acquires Shares of Precision BioScien - GuruFocus.com
Precision BioSciences to Participate in Upcoming November Investor Conferences - BioSpace
Precision BioSciences to Present at Two Major Gene Editing Conferences in November | DTIL Stock News - StockTitan
Trading (DTIL) With Integrated Risk Controls - Stock Traders Daily
Gene Editing Tools Market Size, Growth Opportunities, - openPR
Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B - Business Wire
JANUS HENDERSON GROUP PLC's Strategic Acquisition in Precision B - GuruFocus.com
Precision BioSciences stock hits 52-week low at $7.94 By Investing.com - Investing.com Canada
Precision BioSciences stock hits 52-week low at $7.94 - Investing.com
Highbridge Capital Management's Strategic Acquisition of Precisi - GuruFocus.com
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations - PR Newswire
What is HC Wainwright's Forecast for DTIL FY2024 Earnings? - MarketBeat
Research Analysts Offer Predictions for DTIL FY2027 Earnings - MarketBeat
(DTIL) Technical Data - Stock Traders Daily
Precision Biosciences CEO Michael Amoroso sells shares worth $24,668 - Investing.com India
Precision Biosciences' general counsel sells $4,815 in stock - Investing.com
Precision Biosciences' general counsel sells $4,815 in stock By Investing.com - Investing.com UK
Precision BioSciences keeps $34 target, Market Perform rating By Investing.com - Investing.com Australia
Precision BioSciences: Q3 Earnings Snapshot - Darien Times
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace
Precision BioSciences keeps $34 target, Market Perform rating - Investing.com
Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 - PR Newswire
Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma - Marketscreener.com
Precision BioSciences (DTIL) Set to Announce Earnings on Monday - MarketBeat
Precision BioSciences to Report Third Quarter Results on November 4, 2024 - BioSpace
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Precision Biosciences Inc Stock (DTIL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Scimeca Dario | General Counsel and Secretary |
Nov 02 '24 |
Option Exercise |
0.00 |
1,836 |
0 |
8,557 |
| Scimeca Dario | General Counsel and Secretary |
Nov 04 '24 |
Sale |
8.19 |
588 |
4,816 |
7,969 |
| Amoroso Michael | President and CEO |
Nov 04 '24 |
Sale |
8.19 |
3,012 |
24,668 |
28,537 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):